Lessons Learned: Medtronic Advises On New Tech Add-On Payment Process
This article was originally published in The Gray Sheet
Device firms applying for a new technology "add-on" payment should take steps to include Medicare beneficiaries in their clinical trials, according to Medtronic Sofamor Danek Reimbursement Group Director Robert Peterson
You may also be interested in...
The device industry's hopes to reduce the Centers for Medicare & Medicaid Services' new technology "add-on" payment threshold are riding on a provision in the House's "Medicare Prescription Drug & Modernization Act" of 2003 (HR 1)
Medtronic Sofamor Danek's InFuse bone graft/LT-Cage lumbar tapered fusion system does not qualify for a new technology add-on payment under the inpatient prospective payment system (IPPS) fiscal 2003 final rule because the device is FDA-approved only for single-level spinal fusion
Strong top-line efficacy in pyruvate kinase deficiency patients who don’t receive regular transfusions looks approvable, analysts say, but Agios will await data in regularly transfused patients.